Day: February 12, 2021

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share, for gross proceeds of approximately $57.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Codiak. In addition, Codiak has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of its common stock, at the public offering price, less underwriting discounts and commissions. All the shares to be sold in the proposed offering will be sold...

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $19.00 per share. All shares of common stock in the offering are being offered by Oncorus. The gross proceeds to Oncorus from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $57.0 million. In addition, Oncorus has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is...

SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a price to the public of $26.75 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be approximately $175.2 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on February 17, 2021, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 982,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions.BofA Securities, Jefferies and SVB Leerink are acting as the joint...

GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $110 million. All of the shares are being offered by NexImmune. In addition, NexImmune has granted the underwriters a 30-day option to purchase up to an additional 970,650 shares of common stock at the initial price to the public less underwriting...

CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.The Company also has granted...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.MEDFORD, Ore., Feb. 11, 2021 (GLOBE NEWSWIRE) — Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a multi-state cannabis company with operations and assets in Oregon and Michigan, is pleased to announce that it has entered into a letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and agent (the “Agent”), has agreed to offer for sale, 13,350,000 Special Warrants of the Company (the “Special Warrants”), on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.225 (the “Issue Price”) for total gross proceeds...

BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Decibel. In addition, Decibel has granted the underwriters a 30-day option to purchase up to an additional 1,059,300 shares of common stock at the public offering price, less underwriting discounts and commissions.Decibel’s common stock is expected to begin trading on the Nasdaq Global Select Market on Friday, February 12, 2021, under the symbol “DBTX.” The gross proceeds of the offering, before deducting...

New Proprietary Dietary Supplement Contributes to NormalBone and Cartilage Health and Joint FlexibilityOsteodome Is Second Product to Be Marketed throughout the UKDuring First Quarter 2021EU Distribution Network Grows to 1500 Pharmacies with Access to Additional 50,000CHICAGO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the company”) (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, announced today the launch of a new, proprietary enhanced dietary supplement, Osteodome. Osteodome is a targeted nutritional supplement specifically designed to support normal bone and cartilage function and joint flexibility.Osteodome contains glucosamine,...

LAFAYETTE, Colo., Feb. 11, 2021 (GLOBE NEWSWIRE) — urban-gro, Inc. (NASDAQ: UGRO) (“urban-gro” or the “Company”), a leading global horticulture company that engineers and designs commercial Controlled Environment Agriculture (“CEA”) facilities and integrates complex environmental equipment systems into these high-performance facilities, today announced the pricing of an underwritten public offering of 5,400,000 shares of the Company’s common stock at a public offering price of $10 per share for aggregate gross proceeds of $54,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 810,000 shares of common stock at the public offering price less the underwriting discounts and commissions. The...

CHICAGO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), a leading manufacturer of sorbent minerals, doing business as Amlan International, today announced that the Korean Intellectual Property Office has issued Patent 28958.07.0042 entitled “Clay Product and Uses Thereof.” The patent protects the unique and proprietary mineral-based technology of two of Amlan’s natural feed additives, Varium® for poultry and NeoPrime® for swine, which help global producers meet consumer demands for high-quality antibiotic-free animal protein.The patent provides a methodology for using a natural, mineral-based formulation to mitigate the effects of exposure to pathogenic bacteria and the disease-causing toxins they produce, which damage gut health and function. Amlan’s mineral is specifically selected for...